| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S7440 R21974 |
Bérard, 2017 | Major congenital malformations overall | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.63 [0.23;1.77] | -/55 -/14,847 | - | 55 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6735 R19040 |
Furu, 2015 | Major birth defects | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 0.77 [0.38;1.56] | 9/255 71,374/2,266,875 | 71,383 | 255 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5963 R15339 |
Einarson, 2009 | Major malformations | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 1.44 [0.33;6.27] C | 2/52 25/928 | 27 | 52 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6427 R17646 |
Oberlander, 2008 | Major congenital anomalies | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.53 [0.13;2.13] C | 2/119 3,369/107,320 | 3,371 | 119 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 0.75 [0.45;1.24] | 74,781 | 481 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded